Last reviewed · How we verify
NCT06862557
Pulsed Electromagnetic Field Treatment With Dementia Patients
NA trial testing ECHS AD Device in Alzheimer's Disease in 48 participants. Currently enrolling.
30 April 2026
Quick facts
| Lead sponsor | Herrick Medical LLC |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 1 April 2025 |
| Primary completion | 30 April 2026 |
| Estimated completion | 30 September 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- ECHS AD Device
Conditions studied
- Alzheimer's Disease — all drugs for Alzheimer's Disease →
- Lewy Body Dementia — all drugs for Lewy Body Dementia →
- Vascular Dementia — all drugs for Vascular Dementia →
Sponsor
Herrick Medical LLC
Who can join
Adults 50 to 100, any sex, with Alzheimer's Disease or Lewy Body Dementia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end point is the The Alzheimer's Disease Assessment Scale-Cognitive Subscale. Participants will be followed-up for 9 months post-treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06862557
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ECHS AD Device
Trials testing the same drug.
- NCT05295615 — Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease · NA · recruiting
Other recruiting trials for Alzheimer's Disease
Currently open trials in the same condition.
- NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
- NCT07234942 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants Wit · Phase 1 · recruiting
- NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
- NCT07214727 — A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease · Phase 1 · recruiting
- NCT07105709 — Open-label Extension Study in Participants With Early Alzheimer's Disease · Phase 2 · recruiting
Other Herrick Medical LLC trials
Trials by the same sponsor.
- NCT05295615 — Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease · NA · recruiting
- NCT04851782 — Effects of ivAED™ Device on "Air-in-line" Alarms and Workflow Disruption · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06862557 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Herrick Medical LLC
- Last refreshed: 18 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06862557.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing